Literature DB >> 2595751

The use of aerosolized tobramycin in the treatment of a resistant pseudomonal pneumonitis.

C Y McCall1, W J Spruill, W E Wade.   

Abstract

Aerosolized tobramycin was given to a 68-year-old man with resistant Pseudomonas aeruginosa pneumonitis at a dose of 100 mg every 8 h via a tracheostomy, after the patient failed to respond adequately to parenteral aminoglycoside and ticarcillin therapy. Minimum inhibitory concentration and minimum bactericidal concentration for tobramycin and gentamicin were 16 micrograms/ml and greater than 16 micrograms/ml, which necessitated aerosol administration. Tracheal concentrations 15 min and 4 h after a dose were 1,560 and 930 micrograms/ml. The patient responded and eventually was discharged from the hospital. Thus, monotherapy with an aerosolized aminoglycoside may be effective in some patients with resistant Pseudomonas aeruginosa pneumonitis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2595751     DOI: 10.1097/00007691-198911000-00014

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  2 in total

Review 1.  Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia.

Authors:  G Christopher Wood; Joseph M Swanson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 2.  Inhaled therapeutics for prevention and treatment of pneumonia.

Authors:  Amar Safdar; Samuel A Shelburne; Scott E Evans; Burton F Dickey
Journal:  Expert Opin Drug Saf       Date:  2009-07       Impact factor: 4.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.